CONTEXT: The prevalence of type 2 diabetes (T2D), particularly among young adults, has been rising steadily during the past 2 decades. T2D, especially in its early-onset subtype, is under genetic control. TRIB3 inhibits insulin-stimulated Akt phosphorylation and subsequent insulin action. A TRIB3 gain-of-function polymorphism, Q84R (rs2295490), impairs insulin signaling. OBJECTIVE: The objective of the study was to verify the association of TRIB3 Q84R with: 1) T2D, either subtyped or not according to age at diagnosis (early-onset, <45 yr, or >or= 45 yr); 2) insulin secretion and sensitivity in nondiabetic individuals; or 3) in vitro insulin secretion from isolated human islets. DESIGN: Four different case-control samples comprising a total of 5,469 whites were examined. Insulinogenic and insulin sensitivity indexes and their interplay (disposition index) were assessed in 645 nondiabetic individuals at oral glucose tolerance test, glucose (16.7 mmol/liter)-induced in vitro insulin secretion was assessed in islets isolated from 54 nondiabetic donors. RESULTS: In the whole sample, the R84 variant was nominally associated with T2D (odds ratio 1.17, 95% confidence interval 1.00-1.36, P = 0.04). When stratifying according to age of diabetes onset, R84 carriers had an increased risk of early-onset T2D (odds ratio 1.32, 95% confidence interval 1.10-1.58, P = 0.002). Among 645 nondiabetic subjects, R84 carriers had higher glucose levels (P = 0.005) and lower insulinogenic (P = 0.03) and disposition index (P = 0.02) during the oral glucose tolerance test. R84 islets were more likely to display relatively low glucose-stimulated insulin release (P = 0.04). CONCLUSIONS: The TRIB3 R84 variant is associated with early-onset T2D in whites. Alteration in the insulin secretion/insulin sensitivity interplay appears to underlie this association.
CONTEXT: The prevalence of type 2 diabetes (T2D), particularly among young adults, has been rising steadily during the past 2 decades. T2D, especially in its early-onset subtype, is under genetic control. TRIB3 inhibits insulin-stimulated Akt phosphorylation and subsequent insulin action. A TRIB3 gain-of-function polymorphism, Q84R (rs2295490), impairs insulin signaling. OBJECTIVE: The objective of the study was to verify the association of TRIB3 Q84R with: 1) T2D, either subtyped or not according to age at diagnosis (early-onset, <45 yr, or >or= 45 yr); 2) insulin secretion and sensitivity in nondiabetic individuals; or 3) in vitro insulin secretion from isolated human islets. DESIGN: Four different case-control samples comprising a total of 5,469 whites were examined. Insulinogenic and insulin sensitivity indexes and their interplay (disposition index) were assessed in 645 nondiabetic individuals at oral glucose tolerance test, glucose (16.7 mmol/liter)-induced in vitro insulin secretion was assessed in islets isolated from 54 nondiabetic donors. RESULTS: In the whole sample, the R84 variant was nominally associated with T2D (odds ratio 1.17, 95% confidence interval 1.00-1.36, P = 0.04). When stratifying according to age of diabetes onset, R84 carriers had an increased risk of early-onset T2D (odds ratio 1.32, 95% confidence interval 1.10-1.58, P = 0.002). Among 645 nondiabetic subjects, R84 carriers had higher glucose levels (P = 0.005) and lower insulinogenic (P = 0.03) and disposition index (P = 0.02) during the oral glucose tolerance test. R84 islets were more likely to display relatively low glucose-stimulated insulin release (P = 0.04). CONCLUSIONS: The TRIB3 R84 variant is associated with early-onset T2D in whites. Alteration in the insulin secretion/insulin sensitivity interplay appears to underlie this association.
Authors: Timothy M Frayling; Steven Wiltshire; Graham A Hitman; Mark Walker; Jonathan C Levy; Mike Sampson; Christopher J Groves; Stephan Menzel; Mark I McCarthy; Andrew T Hattersley Journal: Diabetes Date: 2003-07 Impact factor: 9.461
Authors: M Stumvoll; A Fritsche; A Volk; N Stefan; A Madaus; E Maerker; A Teigeler; M Koch; F Machicao; H Häring Journal: Diabetes Date: 2001-04 Impact factor: 9.461
Authors: Chong Wee Liew; Jacek Bochenski; Dan Kawamori; Jiang Hu; Colin A Leech; Krzysztof Wanic; Maciej Malecki; James H Warram; Ling Qi; Andrzej S Krolewski; Rohit N Kulkarni Journal: J Clin Invest Date: 2010-07-01 Impact factor: 14.808
Authors: S Prudente; R Baratta; F Andreozzi; E Morini; M G Farina; A Nigro; M Copetti; F Pellegrini; E Succurro; L Di Pietrantonio; C Brufani; F Barbetti; B Dallapiccola; G Sesti; V Trischitta; L Frittitta Journal: Diabetologia Date: 2010-07 Impact factor: 10.122
Authors: Jiarong Liu; Xuxia Wu; John L Franklin; Joseph L Messina; Helliner S Hill; Douglas R Moellering; R Grace Walton; Mitchell Martin; W Timothy Garvey Journal: Am J Physiol Endocrinol Metab Date: 2009-12-08 Impact factor: 4.310
Authors: A F da Cunha; A F Brugnerotto; A S Duarte; C Lanaro; G G L Costa; S T O Saad; F F Costa Journal: Cell Prolif Date: 2010-06 Impact factor: 6.831
Authors: T Geng; W Hu; M H Broadwater; J M Snider; J Bielawski; S B Russo; J H Schwacke; J Ross; L A Cowart Journal: Diabetologia Date: 2013-07-03 Impact factor: 10.122